Medtronic PLC said it acquired Stimgenics LLC, a Bloomington, Ill.-based privately held company developing a spinal cord stimulation therapy.
Financial terms of the deal were not disclosed in a Jan. 8 news release.
Stimgenics offers a spinal cord stimulation waveform known as Differential Target Multiplexed spinal cord stimulation. The therapy is delivered through Medtronic's Intellis platform for treating patients with chronic pain.
Dublin-based medical device company Medtronic said the acquisition is expected to be neutral to the company's fiscal 2020 EPS.